DRIVING PROGRESS

2015 ANNUAL REPORT

IMPROVING OUTCOMES
Recent scientific discoveries are moving lung cancer into the scientific spotlight. LUNGevity’s research funding allows investigators to translate these discoveries into new options for lung cancer patients.

LUNGevity takes a two-pronged, strategic approach to funding research by focusing on early detection and more effective treatment. In fact, LUNGevity is the only lung cancer nonprofit with a programmatic focus on early detection. Projects are carefully chosen to answer key questions that will most directly benefit the overall survival and quality of life of people with a lung cancer diagnosis.

As a thought leader in the lung cancer community, LUNGevity seeks to address not only the scientific needs in lung cancer research but also the systemic obstacles to progress in both the creation and delivery of care to patients, fully engaging the patient in the process. We identify patient challenges and unmet needs and then develop solutions.

LUNGevity continues to be the go-to organization for those seeking information, resources, and support for themselves or their loved ones. We partner with a wide variety of agencies and nonprofits to help patients make informed decisions in their health care.

As leaders in the lung cancer arena, we are committed to accelerating improved outcomes for lung cancer patients. We are working toward a world where no one dies of lung cancer.
Dear Friends,

We’re living in a truly transformational time of scientific progress and advances in treatment for people living with lung cancer. The pace of progress continues with no sign of slowing down.

In the past year alone, we saw FDA approvals of six drugs for lung cancer patients. These included two immunotherapy drugs, three new targeted therapies for patients with advanced or metastatic non-small cell lung cancer, and a drug that enhances the efficacy of two forms of chemotherapy.

At LUNGevity, we’ve never wavered in our commitment to changing outcomes for people diagnosed with lung cancer. Our scientific research program funds studies with the greatest potential to impact patient outcomes in the near future.

LUNGevity awards tackle lung cancer in two major ways: detecting it early before the disease has spread and treating it more effectively. With this strategic approach, our research translates discovery into clinical advancements for patients so that people with lung cancer can live longer and better lives.

In 2015, LUNGevity launched four critical multi-year, multi-stakeholder initiatives to improve outcomes for people diagnosed with lung cancer.

The initiatives are focused on: ensuring that the patient’s voice and needs are incorporated into research, development, and policy; improving how patients receive information; ensuring that patients have access to precision treatments; and breaking down the barriers for patients to participate in clinical trials.

**PROJECT TRANSFORM** A collaboration between LUNGevity and Johns Hopkins University. Project Transform is an innovative approach to understanding treatment preferences of lung cancer patients. It encompasses core principles of patient-centered outcomes research (PCOR), in line with LUNGevity’s mission of providing a voice to the lung cancer patient. The goal of Project Transform is to change the paradigm in lung cancer from assumptions being made about patient wishes to evidence-based conclusions about patient needs and desires.

**REACHING THE UNREACHED** This initiative is focused on understanding why patients are not receiving information about their diagnosis and treatment options, and then addressing the issues. The goal is to get accurate, timely, and understandable information about a lung cancer diagnosis, treatment options, and “what’s next” into the hands of people to empower them to fully participate in their treatment decisions.

**TAKE AIM AT LUNG CANCER** The goal of this initiative is to ensure that all patients have access to precision medicine—that they are tested at diagnosis for the molecular profile of their tumors, given access to therapies or clinical trials that are targeted at their cancer’s mutations, and have the information that they need to participate in the decision-making process. In partnership with the Association of Community Cancer Centers and CHEST, the Take Aim initiative also addresses the information gaps and biases that exist with healthcare professionals to help change practice behavior.

**CLINICAL TRIALS INITIATIVE** This initiative is focused on breaking down the barriers for lung cancer patients to participate in clinical trials. It includes the creation of a patient-centric clinical trial finder app, multi-media patient education, a Clinical Trials Ambassador program, and change in treatment behavior so that clinical trials go from being seen as a last resort to being considered an early treatment option.

This year we relaunched our website to provide comprehensive, medically vetted information in a multi-media format to help patients and their families make informed choices throughout their lung cancer journey. Our goal is to empower anyone navigating a lung cancer diagnosis to play an active role in their healthcare decisions by providing the most easily accessible, accurate, and up-to-date resources available.

LUNGevity continues in its commitment to provide support resources, educate the public about lung cancer, and build a strong community for those affected by the disease. Our largest national HOPE Summit survivorship conference to date in Washington, DC, brought together over 250 survivors and caregivers, and our regional conferences continue to grow.

Tens of thousands of supporters attended our LUNGevity-sponsored events in 2015, including our signature Breathe Deep Walks and Runs, the nation’s largest grassroots lung cancer event program.

LUNGevity has been recognized by Charity Navigator, the nation’s most trusted charity evaluator, with its prestigious four-star rating. We will continue to be excellent stewards of your donations in the coming years.

Lung cancer is a complicated disease, but ultimately a manageable one. Thanks to the support of our donors, corporate sponsors, and amazing event participants and volunteers, we face 2016 with great optimism and determination. We continue to strive diligently to improve outcomes for people living with lung cancer and to create a world where no one dies of this disease.

Sincerely,

Andrea Ferris
President and Chairman

Andrea Ferris

Dear Friends,

We’re living in a truly transformational time of scientific progress and advances in treatment for people living with lung cancer. The pace of progress continues with no sign of slowing down.

In the past year alone, we saw FDA approvals of six drugs for lung cancer patients. These included two immunotherapy drugs, three new targeted therapies for patients with advanced or metastatic non-small cell lung cancer, and a drug that enhances the efficacy of two forms of chemotherapy.

This progress is particularly exciting for those who have worked in the lung cancer arena for years. Patients, scientists, healthcare providers, and advocates continue to push forward against great odds to achieve their goals.

At LUNGevity, we’ve never wavered in our commitment to changing outcomes for people diagnosed with lung cancer. Our scientific research program funds studies with the greatest potential to impact patient outcomes in the near future.

LUNGevity awards tackle lung cancer in two major ways: detecting it early before the disease has spread and treating it more effectively. With this strategic approach, our research translates discovery into clinical advancements for patients so that people with lung cancer can live longer and better lives.

In 2015, LUNGevity launched four critical multi-year, multi-stakeholder initiatives to improve outcomes for people diagnosed with lung cancer.

The initiatives are focused on: ensuring that the patient’s voice and needs are incorporated into research, development, and policy; improving how patients receive information; ensuring that patients have access to precision treatments; and breaking down the barriers for patients to participate in clinical trials.

**PROJECT TRANSFORM** A collaboration between LUNGevity and Johns Hopkins University. Project Transform is an innovative approach to understanding treatment preferences of lung cancer patients. It encompasses core principles of patient-centered outcomes research (PCOR), in line with LUNGevity’s mission of providing a voice to the lung cancer patient. The goal of Project Transform is to change the paradigm in lung cancer from assumptions being made about patient wishes to evidence-based conclusions about patient needs and desires.

**REACHING THE UNREACHED** This initiative is focused on understanding why patients are not receiving information about their diagnosis and treatment options, and then addressing the issues. The goal is to get accurate, timely, and understandable information about a lung cancer diagnosis, treatment options, and “what’s next” into the hands of people to empower them to fully participate in their treatment decisions.

**TAKE AIM AT LUNG CANCER** The goal of this initiative is to ensure that all patients have access to precision medicine—that they are tested at diagnosis for the molecular profile of their tumors, given access to therapies or clinical trials that are targeted at their cancer’s mutations, and have the information that they need to participate in the decision-making process. In partnership with the Association of Community Cancer Centers and CHEST, the Take Aim initiative also addresses the information gaps and biases that exist with healthcare professionals to help change practice behavior.

**CLINICAL TRIALS INITIATIVE** This initiative is focused on breaking down the barriers for lung cancer patients to participate in clinical trials. It includes the creation of a patient-centric clinical trial finder app, multi-media patient education, a Clinical Trials Ambassador program, and change in treatment behavior so that clinical trials go from being seen as a last resort to being considered an early treatment option.

This year we relaunched our website to provide comprehensive, medically vetted information in a multi-media format to help patients and their families make informed choices throughout their lung cancer journey. Our goal is to empower anyone navigating a lung cancer diagnosis to play an active role in their healthcare decisions by providing the most easily accessible, accurate, and up-to-date resources available.

LUNGevity continues in its commitment to provide support resources, educate the public about lung cancer, and build a strong community for those affected by the disease. Our largest national HOPE Summit survivorship conference to date in Washington, DC, brought together over 250 survivors and caregivers, and our regional conferences continue to grow.

Tens of thousands of supporters attended our LUNGevity-sponsored events in 2015, including our signature Breathe Deep Walks and Runs, the nation’s largest grassroots lung cancer event program.

LUNGevity has been recognized by Charity Navigator, the nation’s most trusted charity evaluator, with its prestigious four-star rating. We will continue to be excellent stewards of your donations in the coming years.

Lung cancer is a complicated disease, but ultimately a manageable one. Thanks to the support of our donors, corporate sponsors, and amazing event participants and volunteers, we face 2016 with great optimism and determination. We continue to strive diligently to improve outcomes for people living with lung cancer and to create a world where no one dies of this disease.

Sincerely,

Andrea Ferris
President and Chairman
LUNGevity Funds the Science That Matters to Patients

The past few years have witnessed unprecedented advances in our understanding of the underlying mechanisms of the disease, as well as in new treatment options.

LUNGevity takes a two-part, strategic approach to funding research by focusing on early detection and more effective treatment. With the guidance of the dedicated experts on our Scientific Advisory Board, we fund the science that will have the greatest impact on survivorship and quality of life for patients.

The complex nature of lung cancer requires personalized management approaches for patients. Options have expanded from the three mainstays of lung cancer treatment—chemotherapy, surgery, and radiation—to include targeted therapy, angiogenesis inhibitors, and, most recently, immunotherapy. Targeted therapy blocks specific functions in a cell and stops cancer cells from growing. Angiogenesis inhibitors block the formation of new blood vessels that supply nutrition to cancer cells. Immunotherapy enables the body’s own immune system to launch an attack against cancer cells. LUNGevity awardees are striving to take lung cancer treatment to the next level by finding the most effective way to use these new therapies.

The research community has also made considerable advances in the detection and diagnosis of lung cancer. Doctors can now use low-dose computed tomography (LDCT) in high-risk populations to detect lung cancer early, when it is most treatable. With the goal of making early detection more widely available to a broader population, LUNGevity awardees are researching how to diagnose indeterminate nodules found on CT scans, risk-stratify the population to better identify who should be screened, and develop a blood- or sputum-based test to detect lung cancer at an early stage.
**PROGRESS IN RESEARCH**

LUNGevity is proud of the advances being made by the talented investigators we fund. This year we are pleased to report on the progress of previously funded LUNGevity projects that may improve outcomes for patients.

**EARLY DETECTION**

LUNGevity’s awarded early detection projects focus on developing noninvasive ways to diagnose lung cancer early.

Cancer cells make RNAs and proteins distinct from those of normal lung cells. Based on these differences, LUNGevity awards are developing tests that would be easy to implement. These tests would not require surgical biopsies, would be used to screen both high- and low-risk people, and would eventually become part of a routine physical examination at a doctor’s office.

Feng Jiang, MD, PhD
University of Maryland, Baltimore
Sanford Stass, MD
University of Maryland, Baltimore

**SPUTUM BIOMARKERS FOR THE EARLY DETECTION OF LUNG CANCER**

All cells produce molecules called RNA, which are usually “copied” to make proteins. However, not all RNA is copied into proteins. Dr. Feng Jiang is studying one such group of RNAs, called non-coding RNA (ncRNA). His team discovered that sputum of lung cancer patients contains cells that make unique ncRNAs. They are using an innovative technology called deep sequencing to study these unique ncRNAs and develop a signature for the early detection of lung cancer.

This approach has the added advantage of not requiring a surgical biopsy—ncRNA extracted from cancer cells in sputum can be studied directly. With LUNGevity funding, Dr. Jiang is confirming the validity of these new biomarkers in early-stage cancer patients whose CT scan indicates the presence of lung nodules. This research could ultimately lead to the development of a practical, easily implemented sputum-based test for the early detection of lung cancer.

Jennifer Beane, PhD
Boston University

**BIOMARKERS FOR THE EARLY DETECTION OF LUNG CANCER**

Some high-risk smokers have patches of abnormal lung cells called “pre-malignant lesions (PMLs).” These lesions can either change back to normal or progress toward squamous cell lung cancer. With LUNGevity funding, Dr. Jennifer Beane, a Career Development Awardee, is studying the differences between PMLs and normal lung cells. She used a new technology called RNA-sequencing and found that cells from cancerous lesions derive energy differently than normal lung cells. Squamous cancer cells, on the other hand, produce proteins less like normal lung cell proteins, including many associated with inflammation. These different proteins can be picked up in a blood test that accurately detects squamous cell lung cancer.

Dr. Miller and his group are now validating the protein biomarker panel in patients with squamous cell lung cancer. They are also working to discover proteins expressed by adenocarcinoma cells that are found in blood and may be useful for diagnosis.

Eric Haura, MD
A. Lee Moffitt Cancer Center & Research Institute

**TARGETING SRC AND STAT5 SIGNALING IN EGFR-DRIVEN NON-SMALL CELL LUNG CANCER**

Non-small cell lung cancer (NSCLC) patients who test positive for an EGFR mutation are treated with drugs called tyrosine kinase inhibitors, also known as targeted therapies. Erlotinib (Tarceva®), gefitinib (Iressa®), and alfatinib (Gilotrif®) are examples of EGFR inhibitors. Despite working at first, these drugs often fail patients because cancers become resistant to the treatment. Dr. Eric Haura is studying how that resistance develops and the role of a protein called SRC. With LUNGevity funding, he discovered that EGFR-positive lung cancer cells cooperate with SRC, which makes cancer cells multiply in an uncontrolled manner. When these cells are treated with an SRC-specific targeted therapy, they stop growing. Building on these findings, Dr. Haura is now testing the combination treatment of an EGFR inhibitor and SRC inhibitor in patients with EGFR-positive adenocarcinoma in a phase I clinical trial. He has also developed new technology to better understand SRC inhibitor drugs and identify new uses for these drugs.

Rebecca Heist, MD, MPH
Massachusetts General Hospital

**IDENTIFYING TUMOR GENOMIC CHANGES IN LUNG CANCERS**

The goal of precision medicine is to match cancer patients with the right therapies. Targeted therapies have shown great promise in this regard. However, up to 40% of patients with lung cancer do not test positive for a known target. Dr. Rebecca Heist and her team are studying this group of patients with funding from LUNGevity. Using next-generation DNA sequencing technology, she has identified genomic changes in this group of patients that may be targetable.

Dr. Heist is performing studies to investigate whether the identified alterations are driving cancer growth and can be treated with targeted medications.

John Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center
David Carbone, MD, PhD
The Ohio State University

**PREDICTIVE BLOOD-BASED MARKERS OF RESPONSE TO VEGF INHIBITORS IN NSCLC**

Cancer cells are greedy. They need a constant supply of nutrition and oxygen through blood circulation. To do that, cancer cells make chemicals that attract blood vessels, a process known as angiogenesis. Drugs that inhibit angiogenesis are already being used to treat lung cancer patients. Unfortunately, not all patients respond to angiogenesis inhibitors. Dr. John Heymach and Dr. David Carbone are studying what determines whether a patient will respond. With the help of LUNGevity funding, he and his colleagues have discovered that some non-small cell lung cancer (NSCLC) patients have high levels of certain proteins, such as HGF and MMPs, in their blood and that these patients are more likely to be resistant to anti-angiogenesis drugs. This study is among the first of its kind to use these biomarkers in the blood to predict whether a patient will benefit from angiogenesis inhibitors. It also lays the foundation for future clinical trials using new combinations of drugs to try to block the emergence of drug resistance.
From 25% of people with lung adenocarcinoma test positive for a KRAS mutation. Unfortunately, to date there has not been a successful treatment to target this mutation. Dr. Mark Onaitis is interested in understanding how the KRAS gene helps cancer cells grow. Through a LUNGevity grant, and using mice to study how adenocarcinomas develop, he stumbled upon an unexpected finding: not all lung cells grow in response to the KRAS mutation. Clara cells and broncho-alveolar cells—two different types of cells found in the lungs—responded differently to KRAS mutations. While Clara cells did not grow in response to a mutated KRAS, broncho-alveolar cells grew uncontrollably and formed lung cancer. His work has wide-ranging implications, especially for how we can keep the effects of the KRAS mutation in check.

Lauren Averett Byers, MD
The University of Texas MD Anderson Cancer Center

Denise R. Alberts, MD
David Geffen School of Medicine at UCLA
Professor and Chair of Research Radiology

Nasser K. Altori, MB, BCH
New York Presbyterian/Weill Cornell Medical Center
Professor of Cardiothoracic Surgery
Chief, Division of Thoracic Surgery

Philip D. Bonomi, MD
Rush University Medical Center
Alisa Pink Wirth Professor of Medical Oncology
Director, Division of Hematology-Oncology

Julie R. Braham, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Director of the Thoracic Oncology Program
Associate Professor of Oncology
Director, Upper Aerodigestive (UAD) Program
Internim Director, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Bayview

David P. Carbone, MD, PhD
The Ohio State University
Professor, Division of Medical Oncology
Barbara J. Bonner Chair in Lung Cancer Research
Director of the Thoracic Oncology Center
International Association for the Study of Lung Cancer (IASLC) President

Martin A. “Mac” Cheever, MD
Cancer Immunotherapy Trials Network Principal Investigator

Fred Hutchinson Cancer Research Center Member

University of Washington Professor of Medicine/Oncology

Steven H. Dubinett, MD
David Geffen School of Medicine at UCLA
Chief, Division of Pulmonary and Critical Care Medicine
Senior Associate Dean for Translational Research
Associate Vice Chancellor for Research Director, Clinical and Translational Science Institute (CTSI)

Edward W. Gabrielson, MD
Johns Hopkins University School of Medicine
Professor of Pathology and Oncology

John V. Heymach, MD, PhD
The University of Texas MD Anderson Cancer Center
Professor and Chairman, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine

James R. Jett, MD
National Jewish Health Professor of Medicine

Robert L. Kyle, MD
University of Colorado Denver
Professor of Medicine and Cancer Biology
Denver VAMC Associate Chief of Staff Research

J. Jack Lee, PhD, DDS
The University of Texas MD Anderson Cancer Center
Professor of Biostatistics
Kenedy Foundation Chair in Cancer Research

Scott M. Lippman, MD
University of California, San Diego
Director, Moores Cancer Center
Chugai Pharmaceutical Chair Professor of Medicine

Pierre P. Massion, MD
Vanderbilt Ingram Cancer Center
Cornelius Vanderbilt Chair in Medicine
Vanderbilt University School of Medicine
Professor of Medicine and Cancer Biology Director, Thoracic Program

Charles M. Rudin, MD, PhD
Memorial Sloan Kettering Cancer Center
Professor and Chief, Thoracic Oncology Service

Lawrence H. Schwartz, MD
Columbia University Medical Center
James Picker Professor and Chairman, Department of Radiology

New York Presbyterian/Columbia University Medical Center Radiologist-in-Chief

Lucia V. Sequist, MD, MPH
Harvard Medical School
Associate Professor of Medicine

Massachusetts General Hospital Cancer Center-Center for Thoracic Cancer Attending Physician

Steven J. Skates, PhD
Harvard Medical School and Massachusetts General Hospital
Associate Professor

Anrum E. Spira, MD, MSc
Boston University
Professor of Medicine, Pathology and Bioinformatics

Alexander Graham Bell Professor in Healthcare Entrepreneurship

Chief, Section of Computational Biomedicine

Margaret R. Spitz, MD, MPH
Baylor College of Medicine
Professor, Dan L. Duncan Cancer Center

### CAREER DEVELOPMENT Awardees

LUNGevity Career Development Awards support the next generation of lung cancer researchers to improve early detection and treatment of lung cancer. It is critical to keep the best and brightest in the field of lung cancer research. We provide support and training that propel their successful careers.

This support entails both funding and mentorship. Awardees participate in scientific meetings as non-voting members of the Scientific Advisory Board. They also have the opportunity to present their findings three times during their award term to the leaders in the field, receive communications training, meet with survivors and donors, and network with their fellow researchers. This networking has already resulted in a number of promising collaborations.

### SCIENTIFIC ADVISORY BOARD

LUNGevity strategically invests funds with the support of a world-class Scientific Advisory Board composed of leaders in their respective fields. This board meets twice a year to share new scientific developments, discuss research strategy, oversee ongoing funded projects, and review grant proposals. These leaders in the fields of proteomics, biostatistics, radiology, immunotherapy, and others are instrumental in improving the outcomes for lung cancer patients.
LUNGevity provides support that patients need

Through our online peer-to-peer and in-person support programs, LUNGevity connects, educates, and empowers survivors and caregivers. We continue to develop new patient resources to address unmet needs of people navigating a lung cancer diagnosis.

Comprehensive Lung Cancer Resource
This past year, we relaunched the LUNGevity website as an online resource for everyone affected by lung cancer. Taking a holistic approach to helping survivors manage the disease, the new site provides access to a variety of vital information and supportive resources. The robust Lung Cancer 101 section of the Foundation website has educational content, developed and vetted by a medical editorial board, that will help patients and their families navigate a lung cancer diagnosis.

Peer-to-Peer Support
Through our LifeLine Program, we continue to offer one-on-one support by matching patients and caregivers to Support Mentors who have had similar experiences. LUNGevity LifeLine is the referral partner for over a dozen organizations, including Imerman Angels and Cancer Care, as well as major medical institutions, including Vanderbilt University Medical Center, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, Cancer Treatment Centers of America, and Cleveland Clinic.

LUNGevity Lung Cancer Support Community
LUNGevity’s Lung Cancer Support Community (LCSC), the largest online lung cancer support network, is a moderated message board where people can share the latest lung cancer information and resources. With over 450,000 posts, a patient or family member can find information on all aspects of managing lung cancer.

LUNG Cancer Clinical Trial Matching Service
LUNGevity partners with EmergingMed to help patients with the decision of whether to participate in a clinical trial. This free, confidential, personalized service helps patients seeking new treatment options to more easily identify those lung cancer clinical trials for which they may be eligible.

Caregiver Resource Center
This unique online resource, which was expanded this year with new materials, offers support and practical advice to caregivers through information, videos, and tip sheets. Caregivers learn what to expect after a lung cancer diagnosis, what questions to ask, how to be a healthcare advocate for the patient, and how to take care of themselves as well.

In-Person Survivorship Programs
LUNGevity’s HOPE Summit conferences provide an opportunity for survivors and caregivers to come together in a supportive and educational environment. Attendees learn about advances in research and treatment, developments in health and nutrition, and improving communications with caregivers and medical professionals. The conferences feature inspirational speakers, medical expert forums, and opportunities for lung cancer survivors to share their stories and connect with other survivors. The program continues to grow in attendance and impact. Regional HOPE Summits were held in Nashville, Houston, Dallas, Columbus, and Seattle, and the fifth annual National HOPE Summit was held with record attendance—over 250 survivors and caregivers—in Washington, DC, in May. After the conference, survivors stay in touch through dedicated Facebook groups, building a virtual community of support.
LUNGevity launched a comprehensive lung cancer resource this year. The multi-media approach focuses on translating the complexity of lung cancer and medical progress into language that patients and caregivers can understand.

The goal is to empower lung cancer patients and their caregivers to be proactive and well informed when faced with treatment decisions, as well as to enable those at high risk to navigate lung cancer screening. LUNGevity’s new website offers an array of informative resources:

1) Educational videos as well as videos of survivor stories can be found on the LUNGevity website.
2) In-depth informational brochures on treatments, clinical trials, lung adenocarcinoma, and squamous cell lung cancer are available to download or request.
3) Lung Cancer 101 is a guide to help patients and caregivers navigate a lung cancer diagnosis at any stage.
4) The Experts Blog provides insight into issues that affect patients, and includes highlights from major cancer conferences.

LUNGevity’s new website offers an array of informative resources:

- **LUNG CANCER 101** is the comprehensive guide to understanding how lung cancer develops, how it can be detected, and treatment options, and includes a glossary feature.
- Whether you or someone you care about has been diagnosed with lung cancer, we have up-to-date, medically vetted information to help.
- **QUESTIONS TO ASK YOUR DOCTOR** The site provides tips and questions for both patients and caregivers to download before a visit with a healthcare provider.
- **THE EXPERTS BLOG** brings you interviews with the leading experts in lung cancer research. Topics include advances in diagnosis and treatment, along with relevant highlights from the key scientific conferences.
- **EDUCATIONAL VIDEOS** can be found on molecular testing, targeted therapies, and immunotherapy, among other timely topics, featuring leading researchers and thoracic oncologists from across the country.
- **THE LUNGEVITY PATIENT EDUCATION SERIES** offers downloadable brochures with in-depth information on clinical trials, targeted therapies, immunotherapy, lung adenocarcinoma, and squamous cell lung cancer. LUNGevity keeps online and print resources up-to-date to help anyone affected by lung cancer understand their options.

“LUNGevity’s Lung Cancer 101 is an invaluable online resource for patients and caregivers at every stage of lung cancer. My wife and I especially appreciated the questions to ask her doctor; we felt better informed and prepared for our visits.”

**PAUL S., CAREGIVER**
LUNGevity builds community to drive change

LUNGevity excels at mobilizing survivors, families, and friends to shine a spotlight on lung cancer and support our mission.

Grassroots events continued to expand to new communities in 2015. Volunteers created new do-it-yourself ways to support our efforts, while LUNGevity Breathe Deep events continued to engage the whole community—individuals, healthcare centers, businesses, and civic groups—to raise awareness as well as significant funds for lung cancer research and support programs. Together, these grassroots events are helping to create a stronger national movement to change outcomes for people living with lung cancer.

Supporters

Breathe Deep North Shore supporters in Deerfield, Illinois, enthusiastically rally for the cause! LUNGevity’s Breathe Deep series is the nation’s largest network of local events dedicated to lung cancer. The North Shore event will celebrate its 5th year in 2016, bringing together survivors, families, and friends to walk, run, and volunteer to raise funds for life-saving lung cancer research.
Banners at Breathe Deep events proclaim that together we will stop lung cancer.

Animated walkers head up a very large band of supporters at Breathe Deep DC.

All it takes is a cup of lemonade to attract support for lung cancer research.

Breathe Deep walks and runs are extra special when a thriving survivor is a team member.

Families and friends enjoy participating on teams to raise lung cancer awareness in their communities.

Dedicated and capable volunteers make our Breathe Deep events extraordinary.

Participants fill out wearable stickers to proudly display the names of those in whose honor and/or memory they are running or walking.

Hundreds of balloons fill the sky at Breathe Deep North Shore in tribute to those affected by lung cancer.

Come as you are to any of our colorful Breathe Deep events! These belles are at Breathe Deep Mobile.

This longtime lung cancer survivor is thrilled to attend her fourth Breathe Deep North Shore.

glassybaby hosts an annual lung cancer awareness and fundraising reception in Seattle. A percentage of sales of their lovely votives goes right to LUNGevity programs.

Honor signs recognizing loved ones line the walking path at Breathe Deep Michigan.

Big kids, middlesized kids, and little kids all want to help the lung cancer cause.
**EVENTS**

**LUNGevity GRASSROOTS, BENEFACtor, GALA, AND SPECIAL EVENTS**

July 1, 2014 - June 30, 2015

- **Alabama**
  - Breathe Deep Mobile

- **Arizona**
  - Breathe Deep Phoenix

- **California**
  - Breathe Deep Bay Area
  - Breathe Deep San Diego

- **Colorado**
  - Breathe Deep Fort Collins

- **District of Columbia**
  - Breathe Deep DC
  - LUNGevity’s Musical Celebration of Hope Gala

- **Florida**
  - Breathe Deep Pompano Beach
  - Tampa HOPE Summit

- **Georgia**
  - Breathe Deep Atlanta
  - Breathe Deep Blue Ridge

- **Illinois**
  - Breathe Deep Busse Woods
  - Breathe Deep Chicago Golf Outing—Long Grove
  - Breathe Deep Chicago Yogathon—Highland Park
  - Breathe Deep DuPage—Naperville
  - Breathe Deep Huntley
  - Breathe Deep Kankakee
  - Breathe Deep Lake Arlington—Arlington Heights
  - Breathe Deep North Shore—Deerfield
  - The John Whiteside/Beatrice Green Memorial Breathe Deep—Arlington Heights
  - Ping Pong & Pour—NYC

- **Indiana**
  - Breathe Deep Chicago Marathon
  - Vernon Hills

- **Iowa**
  - Breathe Deep Des Moines

- **Louisiana**
  - Breathe Deep Baton Rouge

- **Maryland**
  - Arista Ball for Hope—Bethesda
  - Breathe Deep Baltimore
  - Breathe Deep Columbia
  - Hats, Pumps, & Pearls—Sault Taliana

- **Massachusetts**
  - Breathe Deep Boston
  - Upstate Lung Cancer’s 6th Annual Concert Benefit—Boston

- **Michigan**
  - Breathe Deep Ann Arbor
  - Breathe Deep Michigan

- **Missouri**
  - Breathe Deep Kansas City

- **New Jersey**
  - Breathe Deep South Jersey—Pennsauken

- **New York**
  - Breathe Deep Albany
  - Breathe Deep CNY—Liverpool
  - Breathe Deep NYC
  - LUNGevity’s Celebration of Hope Gala—NYC
  - Ping-Pong & Pout—NYC
  - Team Run As One—TCS New York City Marathon

- **North Carolina**
  - Breathe Deep Charlotte
  - Ray Charbonneau Golf Tournament—Cary

- **Ohio**
  - Breathe Deep Cincinnati
  - Breathe Deep Cleveland
  - Breathe Deep Columbus
  - Breathe Deep Newark
  - Columbus HOPE Summit

- **Pennsylvania**
  - Benefit Concert to Fight ALS and Lung Cancer—Willow Grove
  - Breathe Deep Greensburg
  - Breathe Deep NEPA
  - Breathe Deep Philadelphia
  - Breathe Deep Pittsburgh

- **South Carolina**
  - Bowl-a-thon, Shav Air Force Base

- **Tennessee**
  - Breathe Deep Nashville Stache and Lash 5K
  - Nashville HOPE Summit

- **Texas**
  - Breathe Deep DFW
  - Breathe Deep Nashville: Lunch and Learn 2014

- **Utah**
  - Breathe Deep Salt Lake City
  - Breathe Deep Salt Lake City Bowling Tournament

- **Virginia**
  - Breathe Deep Woodbridge: Mary Helen Martin Memorial Luncheon
  - 5th National HOPE Summit—Arlington

- **Washington**
  - Breathe Deep Seattle
  - Lung Cancer Awareness Fundraising Reception at glassybaby—Seattle
  - Ride to Ellen Kickoff Event—Seattle
  - Seattle HOPE Summit

1) Guests danced to songs by Tony Award winner John Lloyd Young at the Broadway-themed Musical Celebration of Hope Gala in Washington, DC.
2) Honorees Teresa Bietetti accepted the Hope Award for Corporate Leadership from Bristol Myers Squibb for its commitment to working across lines of business for the health and well-being of our lung cancer communities in the United States and globally.
3) The (late) Chip Kennett (center) and survivor Jery Sorkin (right), pictured with Chip’s wife, Sheila (left), enjoyed a special evening honoring those who are making tremendous progress in research possible.
4) LUNGevity President and Chairman Andrea Fioretti presented the Face of Hope Award to Donna Karan, founder of Donna Karan Intl. and the Urban Zen Foundation, for her efforts to make a difference for those living with cancer.
5) Researchers (left to right) Dr. Timothy Burns, Dr. David Kozono, Dr. John Poirier, and Dr. Viswam Nair congregated during the New York Celebration of Hope Gala to celebrate the remarkable progress in research.
6) DC Gala Chairs Bob Norton and Suzy Pence (right), pictured with Andrea Fioretti (left), put forth extraordinary efforts to plan a memorable event.
7) We are grateful to NY Gala Chairs Ashley and Jason Bennardo for their incredible dedication to stopping lung cancer and for their tireless efforts in creating a wonderful evening.
8) Guests participated in exciting casino games at the LUNGevity Fall Benefit in Chicago.
LUNGevity appreciates every contribution, and we have made a concerted effort to accurately list all donors of significant contributions in fiscal year 2015.

**Deceased**

Wendy Conrad and Emily Chen and Celgene Cancer Treatment

Jane and Steve Caldeira

Katherine and David Boehringer Ingelheim Biotechnology Industry

Baltimore Orioles

Marlene and Michael Astellas USA Foundation

Shari and Jeff Aronson Amgen, Inc.

American Express

Abbott Molecular

of $5000 and above

Individual, Corporate, and Organizational Gifts of $5000 - $9999

of $1000 - $4999 and Organizational Gifts

and Organizational Gifts of $500 and above

Individual, Corporate, and Organizational Gifts of $5000 and above

Individual, Corporate, and Organizational Gifts

2015 Annual Report

Special thanks to our grassroots event coordinators — these dedicated individuals donate their time, energy, and passion to lead our events around the country!
LUNGevity Foundation remained fiscally strong in 2015, thanks to a diverse set of donors. We were able to continue to grow our programs while adding online and offline support resources and new events, increasing the populations we serve.

Charity Navigator awarded LUNGevity a four-star rating, its top score earned only by charities that prove to be transparent, reliable, and fiscally responsible. The financial activities of LUNGevity Foundation were audited by Ostrow, Reisin Berk & Abrams, Ltd. For our complete audited financial statements, please visit our website at www.LUNGevity.org.

**2015 TOTAL REVENUE:** $7,845,986  
**2015 TOTAL PROGRAM EXPENSES:** $5,044,038
### SUMMARY OF PROFIT AND LOSS

**June 30, 2015**

<table>
<thead>
<tr>
<th>Revenues:</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions and grants</td>
<td>$3,682,539</td>
</tr>
<tr>
<td>Special events and other fundraisers</td>
<td>3,864,666</td>
</tr>
<tr>
<td>Interest and dividends</td>
<td>4,008</td>
</tr>
<tr>
<td>Donated goods and services</td>
<td>294,773</td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>$7,845,986</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Program services</td>
<td>$5,044,038</td>
</tr>
<tr>
<td>Management and general</td>
<td>712,805</td>
</tr>
<tr>
<td>Fundraising</td>
<td>970,815</td>
</tr>
<tr>
<td>Special events</td>
<td>1,109,454</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td>$7,837,112</td>
</tr>
</tbody>
</table>

| Change in net assets                | 8,874    |

<table>
<thead>
<tr>
<th>Net assets:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Beginning of year</td>
<td>$3,063,142</td>
</tr>
<tr>
<td>End of year</td>
<td>$3,072,016</td>
</tr>
</tbody>
</table>

### STATEMENT OF FINANCIAL POSITION

**June 30, 2015**

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2015</th>
<th>2014</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$1,497,146</td>
<td>$3,455,436</td>
</tr>
<tr>
<td>Prepaid expenses</td>
<td>207,925</td>
<td>206,010</td>
</tr>
<tr>
<td>Accounts and grants receivable</td>
<td>351,910</td>
<td>1,120,000</td>
</tr>
<tr>
<td>Pledges receivable</td>
<td>1,705,235</td>
<td>656,982</td>
</tr>
<tr>
<td>Security deposits</td>
<td>14,752</td>
<td>14,752</td>
</tr>
<tr>
<td>Property and equipment, net</td>
<td>38,807</td>
<td>31,761</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>$3,815,775</td>
<td>$5,484,941</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES AND NET ASSETS</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Liabilities:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable</td>
<td>$78,573</td>
</tr>
<tr>
<td>Accrued payroll and vacation liabilities</td>
<td>56,141</td>
</tr>
<tr>
<td>Grants payable</td>
<td>600,000</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>9,045</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td>$743,759</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Net assets:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$1,366,781</td>
</tr>
<tr>
<td>Temporarily restricted</td>
<td>1,705,235</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td>3,072,016</td>
</tr>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td>$3,815,775</td>
</tr>
</tbody>
</table>
HOW TO GET INVOLVED

THANK YOU FOR YOUR CONTINUED SUPPORT!
WE HOPE YOU WILL JOIN US IN 2016!

With the ongoing investment of our donors and volunteers, LUNGevity is making an impact on the lives of people affected by lung cancer. This year, there are more ways than ever to get involved.

PARTICIPATE IN A LUNGevity EVENT  Attend a Breathe Deep event near you and join hundreds of lung cancer advocates, survivors, and family members to help drive change for people diagnosed with lung cancer. You can volunteer, start up a team, or create your own unique event!

RAISE MONEY FOR LUNG CANCER RESEARCH AND SUPPORT  You can fundraise by yourself or on behalf of your team through a LUNGevity event, or create a DIY event in your community. We have the tools to help you succeed. An online tribute fund is a meaningful way to honor someone impacted by lung cancer.

RAISE AWARENESS FOR LUNG CANCER  LUNGevity has a wide variety of materials to help you be an active and effective advocate for those living with lung cancer. Read our online blogs, sign up for our newsletter to keep up with the latest news, or receive our monthly LinkUp Action Alert with volunteer opportunities near you.

CONNECT TO OUR SUPPORT COMMUNITY AND RESOURCES  If you or a loved one is a lung cancer patient, LUNGevity offers many resources for you. The Lung Cancer Support Community Online network and LifeLine Support Partner program will connect you with others at any stage of a lung cancer diagnosis. Our website has dedicated Survivor and Caregiver Resource Centers offering practical support for your physical and emotional well-being. Survivors and caregivers can also attend a HOPE Summit, a conference designed especially for you.

For more information on any of these opportunities, or to discuss any ideas you have about how LUNGevity can be more connected to your community, contact Beth Ida Stern, VP of Community Engagement, at 323-380-5394 or bstern@LUNGevity.org.